Skip Navigation


NDT Advance Access originally published online on February 22, 2007
Nephrology Dialysis Transplantation 2007 22(7):2095; doi:10.1093/ndt/gfm057
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/7/2095    most recent
gfm057v3
gfm057v2
gfm057v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gross, P.
Right arrow Articles by Pistrosch, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, P.
Right arrow Articles by Pistrosch, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

PPAR agonists in diabetic nephropathy

Email: peter.gross{at}mailbox.tu-dresden.de

Sir,

A recent Editorial Comment (Nephrol Dial Transplant 2006; 21: 2696–2702) considered the role of PPAR agonists in diabetic nephropathy; it also addressed other nephropathies. In the former category, in the section on observations in humans, the authors’ comments are almost exclusively limited to UAE (urinary albumin excretion rate) before and after thiazolidinedione. In terms of kidney function this is a kind of ‘black-box’ approach, since nobody knows for sure by which molecular or cellular changes UAE comes about. We missed comments by the authors on intrarenal haemodynamic effects of thiazolidinediones in this respect. The authors did not mention recent studies, published in Diabetes Care and Diabetes, on these issues by our group. We believe that an editorial comment ought to be fair in giving a careful and well balanced view of the published literature.

Conflict of interest statement. None declared.

Peter Gross and Frank Pistrosch

Nephrologie, Med. Klinik III
Universitätsklinikum C. G. Carus
Dresden, Germany

References

  1. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes (2005) 54:2206–2211.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/7/2095    most recent
gfm057v3
gfm057v2
gfm057v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gross, P.
Right arrow Articles by Pistrosch, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, P.
Right arrow Articles by Pistrosch, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?